Myostatin and markers of bone metabolism in dermatomyositis

Key Takeaway

Patients with dermatomyositis exhibit altered biochemical markers of muscle and bone metabolism alongside functional deficits, highlighting the need for targeted, multi-modal rehabilitation.

Kerschan-Schindl K., Gruther W., Föger-Samwald U., Bangert C., Kudlacek S., Pietschmann P.. (2021). Myostatin and markers of bone metabolism in dermatomyositis. https://doi.org/10.1186/s12891-021-04030-0

Read the original publication →

What this study found

In this cross-sectional study of 20 patients with dermatomyositis (DM), researchers identified significant alterations in key biochemical markers regulating muscle and bone metabolism. Specifically, DM patients showed elevated serum levels of myostatin (a protein that limits muscle growth) and fibroblast growth factor 23 (FGF23) compared to healthy controls. Conversely, levels of Dickkopf-1 (Dkk1), a protein involved in bone remodeling pathways, were significantly lower. The study also confirmed that these biochemical alterations correspond with measurable deficits in muscle strength and physical performance, such as hip flexion strength and mobility on the Timed Up and Go (TUG) test.

Why it matters

Dermatomyositis is a systemic inflammatory disease that severely impacts the musculoskeletal system through chronic inflammation, corticosteroid use, and disuse atrophy. The elevation of myostatin suggests a persistent biochemical drive toward muscle wasting, while altered bone markers point to a disrupted bone-muscle crosstalk. For physical medicine and rehabilitation clinicians, these findings underscore that musculoskeletal decline in DM is not merely functional but deeply rooted in biochemical dysregulation. Objective functional assessments (like the TUG or chair-rising tests) correlate well with strength deficits and should be routinely used alongside biochemical monitoring to design highly individualized, progressive resistance training and bone-loading protocols.

Limitations

The primary limitations of this study include its small sample size of 20 patients and its cross-sectional design, which prevents establishing direct causal relationships between specific biomarker levels and long-term functional decline.

Continue your learning

October 21, 2026

Exercise-based rehabilitation interventions for kinesiophobia after total knee arthroplasty: a systematic review and meta-analysis of randomized controlled trials

Low-certainty evidence suggests structured exercise rehabilitation may reduce kinesiophobia and improve knee function after total knee arthroplasty, though substantial study heterogeneity warrants clinical caution.

Result: Low-certainty evidence suggests structured exercise rehabilitation may reduce kinesiophobia and improve knee function after total knee arthroplasty, though substantial study heterogeneity warrants clinical caution.

October 12, 2026

Physical therapist management of patients with suspected or confirmed osteoporosis – German translation and contextual adaptation of a clinical practice guideline from the Academy of Geriatric Physical Therapy (USA)

Osteoporose

Researchers successfully adapted the APTA Geriatrics osteoporosis guideline for German-speaking clinicians, establishing standardized, evidence-based physical therapy recommendations for bone health and fall prevention.

Result: Researchers successfully adapted the APTA Geriatrics osteoporosis guideline for German-speaking clinicians, establishing standardized, evidence-based physical therapy recommendations for bone health and fall prevention.

August 4, 2026

Therapeutic apheresis: An effective strategy for a combined targeting of circulating lipoproteins, inflammatory markers, PFAS, and microplastics in cardiometabolic and neurodegenerative disease?

Therapeutic apheresis shows promise as a multi-target therapy to reduce circulating lipoproteins, inflammatory markers, and environmental toxins like PFAS and microplastics in chronic disease.

Result: Therapeutic apheresis shows promise as a multi-target therapy to reduce circulating lipoproteins, inflammatory markers, and environmental toxins like PFAS and microplastics in chronic disease.

View all studies